Skip to main content

Lyon Joseph Douglas's Form 4 filing

Corcept Therapeutics Inc (CORT) · filed Apr 2, 2025

Accession no.
0000950170-25-049813
Filed
Apr 2, 2025
Trade date
Mar 31-Apr 1, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 9 non-derivative transactions and 5 derivative transactions. Open-market sales total $20.2M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lyon Joseph DouglasCIK 0001817838Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Mar 31, 2025Common StockMOption exerciseAcquired+35,000$13.56+$474,60044,009Direct
Mar 31, 2025Common StockMOption exerciseAcquired+75,000$16.52+$1,239,000119,009Direct
Mar 31, 2025Common StockMOption exerciseAcquired+40,000$15.82+$632,800159,009Direct
Mar 31, 2025Common StockMOption exerciseAcquired+50,000$19.26+$963,000209,009Direct
Mar 31, 2025Common StockSSaleDisposed−162,008$100.22F3−$16,236,441.7647,001Direct
Mar 31, 2025Common StockSSaleDisposed−32,942$101.37F4−$3,339,330.5414,059Direct
Mar 31, 2025Common StockSSaleDisposed−5,050$102.48F5−$517,5249,009Direct
Apr 1, 2025Common StockMOption exerciseAcquired+650$13.56+$8,8149,659Direct
Apr 1, 2025Common StockSSaleDisposed−650$114.53F6−$74,444.59,009Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Mar 31, 2025Common StockMOption exerciseDisposed−35,000$0.00$056,571Direct
Mar 31, 2025Common StockMOption exerciseDisposed−75,000$0.00$00Direct
Mar 31, 2025Common StockMOption exerciseDisposed−40,000$0.00$00Direct
Mar 31, 2025Common StockMOption exerciseDisposed−50,000$0.00$050,000Direct
Apr 1, 2025Common StockMOption exerciseDisposed−650$0.00$055,921Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $100.00 to $100.98 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F4

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $101.00 to $101.90 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F5

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $102.00 to $102.705 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

F6

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.29 to $114.71 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

Remarks

Chief Accounting & Technology Officer

Read the full filing on SEC EDGAR (opens in a new tab)